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Interleukin-l/J (IL-H?) has been implicated in the pathogenesis of insulin-dependent diabetes mellitus. In the present study we have investigated 
the effects of IL-l/I on glucose metabolism in clonal HIT-T15 j3 cells. In the short-term (1 h), 25 U/ml IL-lb significantly increased the rates of 
insulin release and glucose utilisation, but not glucose oxidation. In contrast, after 48 h, IL-lb inhibited insulin release and glucose utilisation and 
oxidation. By assaying enzymes (hexokinase, glucokinase, pyruvate dehydrogenase, glucose 6-phosphatase) and nucleotides (ATP, ADP) associated 
with the regulation of glycolysis and glucose oxidation, we conclude that the inhibitory effects of IL-lb may be due to impaired glucokinase activity, 
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1. INTRODUCTION 
The cytokine IL-l/3 has been proposed by Nerup et 
al. to be the main effector of B-cell damage during in- 
sulitis [1,2], the inflammatory process which precedes 
the onset of insulin-dependent diabetes mellitus. 
posure to IL-l/3 decreased both glucokinase activity 
and glycolytic flux in HIT-T15 cells. This suggests that 
the primary effect of IL-lfl on glucose metabolism in 
HIT cells may be at the level of glucose phosphory- 
lation. 
Previous studies have shown that short-term (1 h) ex- 
posure of isolated pancreatic islets to IL-I,& stimulates, 
whereas [3,4] longer term (48 h) incubations inhibit in- 
sulin release and biosynthesis [5,6]. Further exposure to 
the cytokine eventually causes P-cell destruction and 
death [5,6]. In vivo, the effects of IL-la are similar to 
in vitro findings: lower doses of IL-lb reduce, whereas 
higher doses promote, the onset of diabetes in the BB 
rat [7]. In addition, whilst acute administration of 
IL-l,& is hypoglycaemic in mice [8,9], chronic ad- 
ministration inhibits glucose-stimulated insulin release 
from the perfused pancreas of treated rats [lo]. 
2. EXPERIMENTAL 
2.1. Materials 
RPM1 1640, antibiotics and foetal calf serum were from Gibco 
Laboratories, Grand Island, NY. Human recombinant IL-lp 
(2.5-S x 10’ LAF units/mg) was either from Collaborative Research 
Inc., Bedford, MA. or from the Glaxo Institute of Molecular 
Biology, Geneva, Switzerland. Radiochemicals were from Amersham 
International, Arlington Heights, IL. All other chemicals and 
biochemicals were of analytical grade and were purchased from 
Sigma Chem. Co., St. Louis, MO, Fisher Scientific, Pittsburgh, PA 
or Boehringer Mannheim Biochemicals, Indianapolis, IN. 
2.2. Ceil culture and insulin secretion 
Several groups have investigated the effects of IL-lfl 
on &cell glucose metabolism. Acute exposure to IL-@ 
increases [1 l] and chronic exposure decreases [6,12] the 
rate of glucose oxidation in pancreatic islets. This sug- 
gests that IL-l,& may act through the inhibition of P-cell 
mitochondrial function. 
HIT-T15 cells were cultured in RPM1 1640 medium as we have 
previously described [14]. On the day of the experiment, culture 
medium was aspirated and replaced with medium supplemented with 
additions as shown. Insulin release was measured in media aliquots 
by Enzyme-Linked Immunosorbent Assay (ELISA) as we have 
previously described [ 131. 
The pancreatic islet comprises a mixed population of 
cell types, and the possibility that IL-la may have dif- 
ferent effects on the metabolism of each cell type can- 
not be excluded. We have therefore investigated the 
effects of IL-la on glucose metabolism in clonal HIT- 
T15 cells. The inhibitory effects of long-term exposure 
to IL-lb on glucose oxidation are confirmed. In addi- 
tion, we show for the first time, that long-term ex- 
2.3. Glucose utikation and oxidation 
Rates of glucose utilisation and oxidation were determined in HIT- 
Tl5 cells (- 3 x lo6 cells/assay) by the rates of 13H] Hz0 formation 
over 1 h from 10 mM D-[5-‘HIglucose (423-456 dpm/nmol) [IS] or 
10 mM D-[6-‘HIglucose (404-446 dpm/nmol) [16] respectively. 
2.4. Enzyme activities 
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Hexokinase activity was assayed in HIT-T15 cell homogenates 
(- 1 X lo6 cells/assay) by the rate of D-[U-i4C]glucose-6-phosphate 
formation from 1 mM D-[UL4C]glucose (1891-1920 dpm/nmol) 
[17]. Soluble glucokinase activity was assayed in the same experiment 
in 100 000 g supernatants prepared from HIT-T15 cell homogenates 
(- 7.5 x lo6 cells/assay), by the rate of D-w-‘4C]glucose-6- 
phosphate formation from 100 mM D-[lJ-‘4C]glucose (159-175 
dpm/nmol) [26]. D-[I-“Clglucose-6-phosphate formed was 
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separated from D-[l-‘4C]glucose by ion-exchange chromatography 
on Dowex-2 formate resin [18]. 
Glucose-6-phosphatase (G6Pase) activity was assayed in HIT-T15 
cell homogenates (-2.5 x lo6 cells/assay) s described in [19], except 
that glucose-6-phosphate was measured radiochemically by the rate 
of D-[1-%]glucose formation from 5 mM D-[I-“klglucose-6- 
phosphate (439-470 dpm/nmol) [20]. 
Pyruvate dehydrogenase (PDH) complex activity (active and total 
forms) was assayed by 14C02 formation from 8 mM [l-‘4C] pyruvate 
(7000-8000 dpm/nmol) in HIT-T15 cell homogenates (-2.5 x 10’ 
cells/assay) prepared and assayed as described in [21]. Total PDH 
complex activity (dephosphorylated form) was determined by in- 
cubating HIT-T15 cell homogenates in the presence of a broad 
specificity protein phosphatase [21]. 
One unit of enzyme activity is defined as that activity catalysing the 
formation of 1 rmol of product per minute at 30°C. 
2.5. Adenine nucleotides 
Adenine nucleotides were determined in neutralised perchloric a id 
extracts [22] of HIT-T15 cells by modified reverse-phase HPLC 
analysis, using tetrabutylammonium hydrogen sulphate (THBS) as a 
pairing agent on a Waters Nova-Pak@ Cl8 column [23]. Nucleotides 
were detected spectrophotometrically at 254nm. Peak identification 
was confirmed against ATP and ADP standards. 
3. RESULTS AND DISCUSSION 
We have recently demonstrated [13] that both the 
short-term stimulatory and the longer term inhibitory 
effects of IL-l,& on HIT-T15 insulin release were maxi- 
mal at a concentration of 25 U/ml (- 1 PM). This con- 
centration of IL-lfl was used in all experiments 
described in the present study. 
Fig. 1 shows the effects of 1 and 48 h exposure to 
IL-l,& on HIT-T15 insulin release, glucose utilisation 
and glucose oxidation. Overall, in short-term incuba- 
tions (1 h), IL-l/3 induced a 57.1 k6.4070 potentiation 
of insulin release. In contrast, longer-term (48 h) ex- 
posure to IL-lfl resulted in a 60% inhibition of insulin 
release. These findings are in general agreement with 
our previous study with HIT-T15 cells [13] and also 
with the effects of IL-lp on isolated pancreatic islets 
[1,21. 
In general, the effects of IL-l,& on HIT-T15 insulin 
secretion were accompanied by similar changes in the 
rates of glucose utilisation, but not glucose oxidation. 
Thus, short-term exposure to IL-lb significantly 
(P< 0.01) increased glucose utilisation, but was without 
effect on glucose oxidation. In contrast, the rates of 
both glucose utilisation and oxidation were inhibited 
following long-term (48 h) exposure to IL-lb. It is per- 
tinent to note that the ratio of glucose utilisation:oxida- 
tion, which was 6.20 +: 0.54 (3) in control incubations 
(n = 3), was not affected by acute or chronic exposure 
to IL-lb (not shown). This might suggest hat any ef- 
fect of IL-Ifl on glucose oxidation is likely to be in- 
direct, via changes in the rate of glucose utilisation, 
rather than through direct inhibition of enzymes of the 
tricarboxylic acid cycle. 
The demonstration that 48 h exposure of HIT-T15 
cells to IL-l,& resulted in inhibition of glucose oxidation 
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Fig. 1. Effects of IL-l@ on insulin secretion, glucose utilisation and 
oxidation in HIT-T15 cells. HIT-T15 cells were cultured in the 
presence or absence of IL-Ifl (25 U/ml) for the times shown. Rates 
of glucose utilisation and oxidation were measured by incubating the 
cells in the presence of D-[5-‘HIglucose and D-[6-3H]glucose respec- 
tively. Insulin release was determined by ELBA. Results are express- 
ed as percent of control and are for 3 and 12 experiments for glucose 
utilisation/oxidation and insulin release respectively. Absolute values 
for control insulin secretion at 1 and 48 hours were 561 k80 and 
13026 + 1836 ,&/ml/106 cells respectively. Absolute values for con- 
trol glucose utilisation and oxidation were 31.6kO.9 and 5.3 + 0.5 
nmol/hr/106 cells respectively. Statistics: **p<O.OI; ***p<O.OOl for 
differences from control (Student’s t-test). 
is in agreement with studies using isolated pancreatic 
islets [6,11,24]. However, no significant effects of 
IL-lfl on glucose utilisation have been reported in islets 
[ 11,241. We have confirmed and extended our observa- 
tions on HIT-T15 glucose utilisation by demonstrating 
precise effects of IL-l,& on the activities of individual 
hexose phosphorylating enzymes (Table I). In the 
short-term, exposure of HIT-T15 cells to IL-l@ (1 h) 
decreased hexokinase activity by 42% (P<O.O5) but 
was without effect on glucokinase. In contrast, longer 
term (48 h) exposure to IL-1P decreased glucokinase 
activity by 32% (P<O.O5), but caused no further in- 
hibition of hexokinase activity above that seen at 1 h 
exposure. These findings contrast with those of Eizirik 
et al. [25], who reported that 48 h exposure of pan- 
creatic islets to IL-l,& (48 h) was without effect on 
glucokinase and hexokinase activities. A possible ex- 
planation for this discrepancy is that in liver, gluco- 
kinase exists in two immunologically distinct, soluble 
and particulate isoforms which may be separated by 
high speed centrifugation [17]. In the present study, 
glucokinase activity was assayed in a 100 000 x g super- 
natant. Here, the soluble form of glucokinase alone 
will be measured [17]. However, Eizirik et al. [25] 
measured glucokinase activity in islet homogenates; 
conditions which would presumably detect both forms. 
Therefore, it is possible that the assay conditions used 
in [25] would not be as sensitive to changes in gluco- 
kinase activity as those described here. 
A recent study [26] has shown that islet G6Pase ac- 
tivity is higher than previously reported [27,28]. This 
suggests that, in addition to hexose phosphorylation, 
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Table I Table II 
Effects of IL-lp on the activity of glycolytic enzymes in HIT-T15 
cells 
Effect of IL-l/3 on the activity of PDH-complex and adenine 
nucleotides in HIT-T15 cells 
Enzyme activities 
&U/lo6 cells) 
Control IL-l/3 (1 h) IL-lb (48 h) Control IL-la (1 h) IL-lb (48 h) 
Glucokinase 113218 92-+ 10 69f7* 
Hexokinase 744klOl 464t22’ 341+ 46* 
Glucose-6-phosphatase 112 f 52 156~1~ 11 148~1~2 
Glycolytic enzyme activities were assayed in HIT-T15 cells 
(- 30 x lo6 cells) as described in the Experimental section and were 
calculated by least squares regression analysis. Results are means f 
SE, for 3 experiments. Statistics: *P<O.OS for difference from con- 
trol (Student’s t-test). 
PDH active form 
(olo total active) 
41.lkS.O 38.6r4.6 69.3 + 7.3* 
PDH total complex 292+44 179+45 335 f 12 
&U/lo6 cells) 
ATP/ADP llSk2.9 14.Okl.9 12.6k3.4 
significant re-conversion of glucosed-phosphate back 
to glucose, i.e. substrate cycling, occurs in the &cell 
and may offer an additional site for controlling glyco- 
lysis. In HIT-T15 cells, G6Pase activity was not 
significantly affected by exposure to IL-lb (Table I). 
This suggests that inhibitory effects on glucokinase ac- 
tivity, and concomitant inhibition of flux through the 
glycolytic pathway, may be larger than predicted by 
maximal enzyme activities alone. 
PDH complex activity was assayed in HIT-T15 cell homogenates 
(- 60 x lo6 cells) and is expressed as the percentage of total complex 
in the active form. Adenine nucleotides were determined as described 
in section 2. Retention times for ATP and ADP were 7.87 kO.21 (16) 
and 18.27 +0.22 (16) min respectively. Intracellular concentrations of 
ATP and ADP in controls were 3.18kO.70 (4) and 0.26&0.04 (4) 
mM respectively (calculated assuming a HIT-T 15 intracellular water 
space of 0.81 pl/ceII [31]). Results are means *SE, for 3 experiments. 
Statistics: *P<O.OS for differences from control (Student’s t-test). 
The long-term inhibitory effect of IL-lb on HIT-T15 
glucose oxidation was further studied at the level of 
pyruvate dehydrogenase (PDH), since a decrease in 
PDH complex activity is one conceivable site of 
cytokine-mediated inhibition. The PDH complex is a 
mitochondrial multienzyme complex catalysing the 
decarboxylation of pyruvate to acetylCoA. The com- 
plex is regulated by reversible phosphorylation (phos- 
phorylation is inactivating), catalysed by an intrinsic 
kinase and by a phosphatase, and by end product in- 
hibition [29]. 
The effects of IL-lp on both total complex and the 
activity state of PDH complex in HIT-T15 cells are 
shown in Table II. Total PDH complex activity (phos- 
phorylated and dephosphorylated forms) was unaf- 
fected by exposure to IL-l,&. In contrast, whilst 
short-term exposure of HIT-T15 cells to IL-lp was 
without effect, 48 h exposure resulted in a 70% in- 
crease in the activity state of PDH complex. In view of 
the decrease in glucose oxidation reported in this, and 
other studies [6,11,24], the increase in the activity state 
of PDH complex in response to long-term exposure to 
IL-1P appears paradoxical. However, Eizirik et al. [25] 
have shown that the rate of [l-r4C] pyruvate decarbox- 
ylation in islets exposed to IL-1P (48 h) increased 2-fold 
from control whilst, at the same time, the rate of D- 
[6-r4C]glucose oxidation was decreased by approxi- 
mately 50% from control. These results, together with 
the present findings might suggest hat the primary ef- 
fect of IL-lb on glucose metabolism may be proximal 
to the PDH reaction; thus whilst IL-l/3 may increase 
the activity state of PDH complex, this may not result 
in increased glucose oxidation. 
One likely consequence of a decreased rate ot glucose 
oxidation in response to IL-l@ (48 h) would be a 
decrease in the intracellular ATP/ADP ratio. This 
would result in inhibition of PDH kinase activity and 
would therefore increase the activity state of PDH com- 
plex [29]. However, there was no significant effect of 
IL-lfl on either the ATP/ADP ratio (Table II) or the 
total adenine nucleotide content (results not shown) of 
HIT-T15 cells following either 1 h or 48 h exposure to 
IL-l,&. In addition, there was no effect of IL-l/3 on the 
NADH/NAD ratio; as indexed by the 1actate:pyruvate 
ratio (results not shown). The precise mechanism by 
which IL-lfi increases the activity state of PDH com- 
plex remains unclear, although modulation of PDH 
phosphatase and/or PDH kinase activities is pre- 
sumably involved. 
In HIT-T15 cells, glucose metabolism is normally 
limited by the rate of entry of glucose into the cell 
130,311. We propose that in HIT-T15 cells exposed to 
IL-lfl, hexose phosphorylation becomes rate-limiting 
for glycolysis. This could explain the decrease in 
glucose utilisation in HIT-T15 cells exposed to IL-lfl 
(48 h). Further, the contribution of hexokinase to hex- 
ose phosphorylation in the intact &cell under physio- 
logical concentrations of glucose is low and thus 
glucokinase activity is likely to be the major determi- 
nant of the rate of hexose phosphorylation [32]. This 
suggests that the primary effect of IL-l@ on glucose 
utilisation may result from a decrease in glucokinase 
activity. 
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